SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,536,000 | -6.0% | 398,885 | +5.0% | 1.48% | +8.5% |
| Q1 2022 | $12,278,000 | +10.8% | 379,875 | -0.0% | 1.36% | +11.4% |
| Q4 2021 | $11,080,000 | +25.5% | 379,975 | +14.7% | 1.22% | +19.3% |
| Q3 2021 | $8,832,000 | +54.0% | 331,140 | +102.3% | 1.02% | +15.6% |
| Q1 2019 | $5,736,000 | +47.7% | 163,691 | +40.0% | 0.88% | +69.5% |
| Q4 2018 | $3,883,000 | -68.4% | 116,886 | -52.2% | 0.52% | -53.2% |
| Q3 2018 | $12,302,000 | -19.8% | 244,356 | -4.7% | 1.12% | -21.0% |
| Q2 2018 | $15,346,000 | +18.8% | 256,401 | -9.1% | 1.41% | +11.4% |
| Q1 2018 | $12,918,000 | -14.1% | 282,056 | -25.3% | 1.27% | +19.3% |
| Q4 2017 | $15,041,000 | +5.9% | 377,461 | +6.3% | 1.06% | +13.7% |
| Q3 2017 | $14,200,000 | +54.9% | 354,955 | +66.8% | 0.94% | +52.0% |
| Q2 2017 | $9,169,000 | – | 212,740 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |